KTLA

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in ...
MarketWatch

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

The MarketWatch News Department was not involved in the creation of this content. The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and ...

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market

Sagimet Biosciences Inc. stock rated Strong Buy on promising drug data and pipeline growth in acne and MASH. Click for this ...
Yahoo Finance

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the ...

Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combina ...